Somatic mutations in acquired pure red cell aplasia.

Clonal hematopoiesis PRCA STAT3 Somatic mutation

Journal

Seminars in hematology
ISSN: 1532-8686
Titre abrégé: Semin Hematol
Pays: United States
ID NLM: 0404514

Informations de publication

Date de publication:
07 2022
Historique:
received: 05 05 2022
revised: 28 06 2022
accepted: 08 07 2022
entrez: 17 9 2022
pubmed: 18 9 2022
medline: 21 9 2022
Statut: ppublish

Résumé

Acquired pure red cell aplasia (PRCA) is a syndrome characterized by anemia and a marked reduction of erythroid progenitor cells with various etiologies. The 3 major subtypes of PRCA are idiopathic PRCA, large granular lymphocytic leukemia-associated PRCA and thymoma-associated PRCA, which are thought to be caused by a T-cell-mediated mechanism. In these 3 subtypes, an expansion of clonal cytotoxic T cells is often detected. In addition, those T cells recurrently harbor somatic mutations of STAT3, a gene coding one of the important signal transducers in the JAK/STAT system. Somatic mutations of clonal hematopoiesis (CH)-related genes, including epigenetic modifying genes, have also been reported, however, the data are still not mature enough upon which to draw conclusion, Somatic mutations of STAT3 and CH-related genes may be unique characteristics of acquired PRCA. However, their involvement in dyserythropoiesis or clinical relevance to the clinical course of those somatic mutations. Mutational landscapes, their involvements in dyserythropoiesis and clinical relevance in acquired PRCA remains unclear, and further investigation is needed.

Identifiants

pubmed: 36115689
pii: S0037-1963(22)00038-5
doi: 10.1053/j.seminhematol.2022.07.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-136

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Toru Kawakami (T)

Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.

Hideyuki Nakazawa (H)

Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.

Fumihiro Ishida (F)

Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan; Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan; Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan. Electronic address: fumishi@shinshu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH